在治疗轴性脊椎关节炎时使用 Certolizumab pegol
Elizabeth Anderson1, Secia Beier2, Julianna Desmarais1
1Oregon Health & Sciences University, Division of Rheumatology, Portland, OR, USA.
Immunotherapy
|March 26, 2024
概括
塞尔科利祖马布佩戈尔有效治疗活跃的轴性脊柱关节炎 (axSpA) 并保持缓解. 现实数据显示长期益处和安全性,包括怀孕期间.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 轴性脊椎关节炎 (axSpA) 是一种慢性,免疫媒介的炎症性疾病.
- 结性脊柱炎和非放射性 axSpA 是这种疾病的关键形式.
- 瘤坏死因子 (TNF) 抑制剂是主动axSpA的推的二线治疗方法.
研究的目的:
- 评估certollizumab pegol在治疗axSpA中的疗效和安全性.
- 为了评估与certollizumab pegol治疗的缓解的长期维持.
- 审查关于certollizumab pegol益处和耐受性的现实世界的证据.
主要方法:
- 对三项大型III期临床试验 (RAPID-axSpA,C-axSpAnd,C-OPTIMISE) 的分析.
- 包括一个大型IV期试验 (CIMAX) 的数据.
- 关于临床疗效和患者结果的现实世界证据的审查.
主要成果:
- 塞尔科利祖马布佩戈尔在治疗活性axSpA和维持缓解方面表现出临床疗效.
- 现实世界的数据证实了疗效,并显示了诸如减少骨损失和脑膜炎风险等益处.
- 该药物在怀孕和哺乳期表现出安全性,观察到10年药物存活率指数.
结论:
- 塞尔科利祖马布佩戈尔 ( Certolizumab pegol) 是一种有效的治疗选择,适用于活跃axSpA.A.患者.
- 长期使用得到现实世界的证据的支持,证明了持续的有效性和安全性.
- 虽然一般耐受性很好,但应该考虑严重感染的风险.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173


